|
|
|
|
Beam Therapeutics Inc (NASDAQ: BEAM) |
|
Price: $21.4600
$1.16 
5.714%
|
| Day's High:
| $22.39
| Week Perf:
| 7.95 %
|
| Day's Low: |
$ 20.86 |
30 Day Perf: |
25.13 % |
| Volume (M): |
3,984 |
52 Wk High: |
$ 35.25 |
| Volume (M$): |
$ 85,501 |
52 Wk Avg: |
$23.72 |
| Open: |
$21.76 |
52 Wk Low: |
$13.53 |
|
|
| Market Capitalization (Millions $) |
1,765 |
| Shares
Outstanding (Millions) |
82 |
| Employees |
190 |
| Revenues (TTM) (Millions $) |
64 |
| Net Income (TTM) (Millions $) |
-377 |
| Cash Flow (TTM) (Millions $) |
-155 |
| Capital Exp. (TTM) (Millions $) |
9 |
Beam Therapeutics Inc
Company Address: 238 Main Street Cambridge 2142 MA
Company Phone Number: 327-8775 Stock Exchange / Ticker: NASDAQ BEAM
|
|
|
Customers Net Income fell by |
BEAM's Customers Net Profit Margin fell to |
-30.3 % |
7.67 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Sat, Apr 5 2025 11:20 PM UTC
Beam Therapeutics, a prominent player in the gene-editing sector, has released promising new data on its investigational therapy, BEAM-302, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) at the 7th Global Research Conference and 10th Patient Congress organized by the Alpha-1 Foundation. The company reported that in the 60 mg cohort (n=3), the treatment led to a...
|
| Clinical Study
Published Sat, Dec 7 2024 4:30 PM UTC
Beam Therapeutics Inc. has made significant strides in the treatment of sickle cell disease, presenting groundbreaking new data from its BEACON Phase 1/2 clinical trial of BEAM-101 during the recent American Society of Hematology (ASH) Annual Meeting. Notably, all seven patients who received BEAM-101 displayed remarkable results: a hemoglobin F (HbF) induction exceeding 60%,...
|
| Clinical Study
Published Tue, Nov 5 2024 2:00 PM UTC
Advancements in Hematology: Beam Therapeutics Innovative Research Amidst Financial Challenges Beam Therapeutics, a leading biotechnology company focused on developing precision genetic medicines through base editing, recently made significant presentations at the American Society of Hematology (ASH) Annual Meeting. The data presented encapsulates crucial insights from thei...
|
| Clinical Study
Published Wed, Jun 26 2024 10:30 AM UTC
Beam Therapeutics Groundbreaking BEAM-302 Enters Clinical Trial for Alpha-1 Antitrypsin Deficiency, While Suppliers Face Financial ChallengesConclusion:Beam Therapeutics Inc. s dosing of the first patient with BEAM-302 in the Phase 1/2 clinical trial for severe alpha-1 antitrypsin deficiency represents a significant advancement in precision genetic medicines. The therapy s ...
|
| Clinical Study
Published Fri, Jun 14 2024 7:00 AM UTC
Beam Therapeutics, a leading biotechnology company specializing in precision genetic medicines through base editing, has announced significant progress in the manufacturing process for BEAM-101, an investigational base editing therapeutic for sickle cell disease (SCD). The company presented data at the European Hematology Association (EHA) Hybrid Congress, highlighting the s...
|
| Per Share |
Current |
| Earnings (TTM) |
-4.54 $ |
| Revenues (TTM) |
0.77 $
|
| Cash Flow (TTM) |
- |
| Cash |
3.43 $
|
| Book Value |
8.92 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-4.54 $
|
| Revenues (TTM) |
0.77 $ |
| Cash Flow (TTM) |
- |
| Cash |
3.43 $
|
| Book Value |
8.92 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
